Skip to Content

Clinuvel Pharmaceuticals Ltd CLVLF

Morningstar Rating
$11.46 −0.09 (0.78%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

CLVLF is trading at a 739% premium.
Price
$11.48
Fair Value
$13.38
Uncertainty
High
1-Star Price
$72.58
5-Star Price
$2.82
Economic Moat
Jwk
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CLVLF is a good fit for your portfolio.

Trading Information

Previous Close Price
$11.55
Day Range
$11.4611.46
52-Week Range
$8.5712.68
Bid/Ask
$10.04 / $10.72
Market Cap
$574.19 Mil
Volume/Avg
850 / 1,978

Key Statistics

Price/Earnings (Normalized)
24.40
Price/Sales
11.24
Dividend Yield (Trailing)
0.28%
Dividend Yield (Forward)
0.28%
Total Yield
0.28%

Company Profile

Clinuvel distributes a single product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient’s quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel’s earnings stem from Europe and the US.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
16

Competitors

Valuation

Metric
CLVLF
AVH
ABBV
Price/Earnings (Normalized)
24.4015.33
Price/Book Value
4.727.2737.05
Price/Sales
11.244.785.47
Price/Cash Flow
21.6015.84
Price/Earnings
CLVLF
AVH
ABBV

Financial Strength

Metric
CLVLF
AVH
ABBV
Quick Ratio
6.386.540.72
Current Ratio
6.867.250.94
Interest Coverage
11.03−17.573.95
Quick Ratio
CLVLF
AVH
ABBV

Profitability

Metric
CLVLF
AVH
ABBV
Return on Assets (Normalized)
19.77%−48.66%14.14%
Return on Equity (Normalized)
23.18%−77.11%172.29%
Return on Invested Capital (Normalized)
22.09%−58.44%27.87%
Return on Assets
CLVLF
AVH
ABBV
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
RrxvbgpfGxzd$632.3 Bil
Vertex Pharmaceuticals Inc
VRTX
YfsxvvcyqKqjrrt$126.7 Bil
Regeneron Pharmaceuticals Inc
REGN
DcmdcbqqqCjmxt$119.2 Bil
Moderna Inc
MRNA
WfkymchSfrp$46.6 Bil
Alnylam Pharmaceuticals Inc
ALNY
JwjzsjjkCcfjyx$32.4 Bil
argenx SE ADR
ARGX
JtcjtgmTgzcc$27.6 Bil
BioNTech SE ADR
BNTX
VgllmltyRykt$20.3 Bil
Biomarin Pharmaceutical Inc
BMRN
PggggdtvkMqnqvl$16.1 Bil
United Therapeutics Corp
UTHR
WtmlhbtPmsw$14.5 Bil
Incyte Corp
INCY
SqyxnqhwBfkfn$12.7 Bil

Sponsor Center